Chargement en cours...
SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of vertebral (VF), nonvertebral (NV...
Enregistré dans:
| Publié dans: | J Endocr Soc |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Endocrine Society
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552091/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-519 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|